Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MB | P02144 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 6/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.36 |
| ▸ | GSK3B | P49841 | 3/20 | 0.34 |
| ▸ | AURKA | O14965 | 2/20 | 0.33 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.33 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.33 |
| ▸ | ABL1 | P00519 | 2/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.33 |
| ▸ | RET | P07949 | 2/20 | 0.33 |
| ▸ | MET | P08581 | 2/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.33 |
| ▸ | PIM1 | P11309 | 2/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.33 |
| ▸ | FLT1 | P17948 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2844929 | 1.00 | MB (0.37) | MBAKR1B1PNMTADRA2AADRA2B | |
| SCHEMBL2844934 | 1.00 | MB (0.37) | MBAKR1B1PNMTADRA2AADRA2B | |
| SCHEMBL2276398 | 0.79 | AKR1B1 (0.40) | MBAKR1B1PNMTADRA2AADRA2B | |
| SCHEMBL24823955 | 0.78 | AKR1B1 (0.42) | MBAKR1B1GSK3BAURKADAPK3 | |
| SCHEMBL1253572 | 0.77 | MB (0.37) | MBAKR1B1GSK3BAURKADAPK3 | |
| SCHEMBL1253576 | 0.77 | MB (0.37) | MBAKR1B1GSK3BAURKADAPK3 | |
| SCHEMBL1254204 | 0.75 | MB (0.38) | MBAKR1B1GSK3BAURKADAPK3 | |
| SCHEMBL23854701 | 0.74 | PNMT (0.41) | PNMTADRA2AADRA2BADRA2CDYRK1A | |
| SCHEMBL15951381 | 0.73 | MB (0.66) | MBAKR1B1GSK3BAURKADAPK3 | |
| SCHEMBL2843135 | 0.73 | PNMT (0.44) | PNMTADRA2AADRA2BADRA2CNNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2687533-B1 | Acrylamide derivatives as FAB I inhibitors | DEBIOPHARM INT SA (CH) | 2017-07-19 | — | — | EP | disclosed |
| EP-2687533-B1 | Acrylamide derivatives as FAB I inhibitors | DEBIOPHARM INT SA (CH) | 2017-07-19 | — | — | EP | disclosed |
| EP-2054422-B1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | DEBIOPHARM INT SA (CH) | 2017-06-14 | — | — | EP | disclosed |
| EP-2054422-B1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | DEBIOPHARM INT SA (CH) | 2017-06-14 | — | — | EP | disclosed |
| US-8895545-B2 | Acrylamide derivatives as Fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2014-11-25 | — | — | US | disclosed |
| US-8895545-B2 | Acrylamide derivatives as Fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2014-11-25 | — | — | US | disclosed |
| US-8895545-B2 | Acrylamide derivatives as Fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2014-11-25 | — | — | US | disclosed |
| EP-2687533-A2 | Acrylamide derivatives as FAB I inhibitors | Affinium Pharmaceuticals, Inc. (CA) | 2014-01-22 | — | — | EP | disclosed |
| EP-2687533-A2 | Acrylamide derivatives as FAB I inhibitors | Affinium Pharmaceuticals, Inc. (CA) | 2014-01-22 | — | — | EP | disclosed |
| US-20130237523-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2013-09-12 | — | — | US | disclosed |
| US-20130237523-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2013-09-12 | — | — | US | disclosed |
| US-8318720-B2 | Acrylamide derivatives as Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2012-11-27 | — | — | US | disclosed |
| US-8318720-B2 | Acrylamide derivatives as Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2012-11-27 | — | — | US | disclosed |
| US-8318720-B2 | Acrylamide derivatives as Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2012-11-27 | — | — | US | disclosed |
| US-20100130470-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100130470-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100130470-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| EP-2054422-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | Affinium Pharmaceuticals, Inc. (CA) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008009122-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008009122-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237523-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | ACR, DBI, AADAC | MB 1888/4885AKR1B1 2500/4885PNMT 3947/4885 |
| US-20100130470-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | ACR, DBI, AADAC | MB 1888/4885AKR1B1 2500/4885PNMT 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.